See more : Y.A.C. Holdings Co., Ltd. (6298.T) Income Statement Analysis – Financial Results
Complete financial analysis of Neuronetics, Inc. (STIM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Neuronetics, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Indofood Agri Resources Ltd. (INDFY) Income Statement Analysis – Financial Results
- Solar A/S (SOLAR-B.CO) Income Statement Analysis – Financial Results
- Enerpac Tool Group Corp. (EPAC) Income Statement Analysis – Financial Results
- Jiangsu Yunyong Electronics and Technology Co.,Ltd (688060.SS) Income Statement Analysis – Financial Results
- Advice Capital Globale (ACIGLO.CO) Income Statement Analysis – Financial Results
Neuronetics, Inc. (STIM)
About Neuronetics, Inc.
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 71.35M | 65.21M | 55.31M | 49.24M | 62.66M | 52.78M | 40.43M | 34.23M |
| Cost of Revenue | 19.64M | 15.48M | 11.65M | 11.55M | 15.39M | 12.45M | 9.63M | 6.62M |
| Gross Profit | 51.71M | 49.72M | 43.66M | 37.69M | 47.27M | 40.33M | 30.80M | 27.61M |
| Gross Profit Ratio | 72.47% | 76.26% | 78.93% | 76.54% | 75.44% | 76.42% | 76.18% | 80.65% |
| Research & Development | 9.52M | 9.34M | 7.92M | 9.20M | 13.75M | 8.23M | 7.94M | 8.22M |
| General & Administrative | 25.43M | 25.52M | 25.55M | 18.24M | 17.46M | 13.67M | 8.57M | 6.93M |
| Selling & Marketing | 47.32M | 49.98M | 37.75M | 32.56M | 42.99M | 38.26M | 27.90M | 21.79M |
| SG&A | 72.74M | 75.50M | 63.30M | 50.80M | 60.45M | 51.93M | 36.47M | 28.72M |
| Other Expenses | 0.00 | 2.20M | 390.00K | 302.00K | 1.57M | -575.00K | 357.00K | -62.00K |
| Operating Expenses | 82.26M | 84.83M | 71.22M | 60.00M | 74.20M | 60.16M | 44.41M | 36.94M |
| Cost & Expenses | 101.90M | 100.32M | 82.88M | 71.55M | 89.59M | 72.61M | 54.04M | 43.57M |
| Interest Income | 24.00K | 2.05M | 3.63M | 4.22M | 2.11M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 5.42M | 4.25M | 4.02M | 4.52M | 3.69M | 3.69M | 2.81M | 1.84M |
| Depreciation & Amortization | 2.01M | 1.65M | 1.06M | 941.00K | 1.07M | 882.00K | 673.00K | 673.00K |
| EBITDA | -22.76M | -31.26M | -26.55M | -21.07M | -26.93M | -19.53M | -12.58M | -8.73M |
| EBITDA Ratio | -31.90% | -47.94% | -47.21% | -42.78% | -38.77% | -37.00% | -31.30% | -25.49% |
| Operating Income | -30.55M | -35.11M | -27.56M | -22.31M | -26.93M | -19.83M | -13.61M | -9.34M |
| Operating Income Ratio | -42.82% | -53.85% | -49.83% | -45.30% | -42.98% | -37.58% | -33.66% | -27.28% |
| Total Other Income/Expenses | 365.00K | -2.05M | -3.63M | -5.14M | -2.11M | -4.26M | -2.45M | -1.90M |
| Income Before Tax | -30.19M | -37.16M | -31.19M | -27.45M | -29.04M | -24.10M | -16.06M | -11.23M |
| Income Before Tax Ratio | -42.31% | -56.99% | -56.39% | -55.75% | -46.35% | -45.66% | -39.72% | -32.82% |
| Income Tax Expense | -24.00K | 2.05M | 4.41M | 4.82M | 5.26M | -575.00K | 3.17M | 1.77M |
| Net Income | -30.19M | -39.21M | -35.60M | -32.28M | -34.30M | -24.10M | -16.06M | -11.23M |
| Net Income Ratio | -42.31% | -60.13% | -64.37% | -65.55% | -54.74% | -45.66% | -39.72% | -32.82% |
| EPS | -1.05 | -1.46 | -1.40 | -1.71 | -1.87 | -2.69 | -1.43K | -1.00K |
| EPS Diluted | -1.05 | -1.46 | -1.40 | -1.71 | -1.87 | -2.69 | -1.43K | -1.00K |
| Weighted Avg Shares Out | 28.66M | 26.90M | 25.48M | 18.84M | 18.38M | 8.95M | 11.22K | 11.22K |
| Weighted Avg Shares Out (Dil) | 28.66M | 26.90M | 25.48M | 18.84M | 18.38M | 8.95M | 11.22K | 11.22K |
Neuronetics to Present at the Piper Sandler 36th Annual Healthcare Conference
MALVERN, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that the...
Neuronetics, Inc. (STIM) Q3 2024 Earnings Call Transcript
Neuronetics, Inc. (NASDAQ:STIM ) Q3 2024 Earnings Call November 12, 2024 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President and Chief Executive Officer Steve Furlong - Chief Financial Officer Conference Call Participants William Plovanic...
CORRECTION—Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results
MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- In a release issued earlier today under the same headline by Neuronetics, Inc. (NASDAQ: STIM), please note that in the second paragraph of the "Stockholders Approve Acquisition of Greenbrook TMS" section, it should say...
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced...
Neuronetics (STIM) Reports Q3 Loss, Lags Revenue Estimates
Neuronetics (STIM) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.33 per share a year ago.
Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results
MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best...
Neuronetics to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call
MALVERN, Pa., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans...
NeuroStar® Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents with Depression
Data selected for oral presentation reinforce previous findings on safety and efficacy Data selected for oral presentation reinforce previous findings on safety and efficacy
Neuronetics and Greenbrook TMS Announce Receipt of Interim Order in Respect of Proposed Arrangement and Provide Details of Shareholder Meetings
MALVERN, Pa. and TORONTO , Oct. 4, 2024 /PRNewswire/ - Neuronetics, Inc. (NASDAQ: STIM) ("Neuronetics") and Greenbrook TMS Inc. (OTCMKTS: GBNHF) ("Greenbrook") today announced that the Ontario Superior Court of Justice (Commercial List) (the "Court") has granted an interim order (the...
Health Care Service Corporation Adds First-Line TMS Coverage for Adolescents
Policy update increases access for millions covered by HCSC BlueCross BlueShield policies Policy update increases access for millions covered by HCSC BlueCross BlueShield policies
Source: https://incomestatements.info
Category: Stock Reports